What payers will ask
Is the clinical benefit the kind payers reward? — Clinical effectiveness
Ensartinib demonstrated a significant improvement in PFS compared to crizotinib in a randomized phase III trial, with a median PFS of 25.8 months versus 12.7 months. However, no OS advantage was demonstrated, and the comparator is outdated in current practice.
Does the economic case hold at the expected price? — Cost effectiveness
No ensartinib-specific cost-effectiveness analysis was identified for the target markets. The available economic evidence from China is not generalizable.
Is there quality-of-life evidence payers weigh? — Quality of life
HRQoL data were collected using established instruments, but results were not statistically significant, and detailed results were primarily available from conference presentations rather than peer-reviewed publications.
Does the safety profile hold up for payers? — Safety and Adverse Effects
Ensartinib has a well-characterized safety profile with a higher incidence of dermatologic AEs compared to crizotinib. Serious AEs and dose modifications are documented, but no direct comparison with other next-generation ALK inhibitors is available.
Was the drug compared against what payers expect? — Comparator Selection
Crizotinib was an appropriate comparator at the time of trial initiation, but it is no longer the standard of care. Current comparators like alectinib and brigatinib are more relevant.
Is the population defined the way payers need it? — Patient Population and Subgroups
The trial population was broadly representative of the target condition, but there were gaps in representation for older adults, Black patients, and those with ECOG 2.
Does the drug fit how care is delivered and paid for? — Care Pathway Integration
Ensartinib fits into existing ALK biomarker testing pathways, requiring no new infrastructure or training.
Are the wider system costs understood? — Resource Use and Cost Implications
No target-market budget impact or resource use data were identified. The available data from China are not applicable.
Would the evidence survive payer scrutiny? — Evidence Quality and Robustness
The evidence is based on a robust phase III trial with high-quality PFS data, but the lack of direct comparison with current standard treatments limits its applicability.
How exposed is the case to uncertainty? — Uncertainty, Sensitivity, and Broader Impacts
High uncertainty remains due to the lack of direct comparison with current first-line treatments and incomplete economic data for target markets.
